Director, National Accounts and Field Reimbursement

Position Summary

Candidates located in the Northeast or Southeast are preferred.

We are seeking a Director of National Accounts and Field Reimbursement who will support the execution of market access strategies for Celcuity’s first commercial product in late-stage Breast Cancer. Reporting to the VP of Market Access, this individual will be responsible for assisting in payer account engagement, managing day-to-day field reimbursement activities, and ensuring smooth operational execution of access plans across national and regional payers, Medicare MACs, and state Medicaid programs.

This role will work cross-functionally with internal stakeholders across Market Access, Medical Affairs, and Commercial teams to ensure alignment and support for Celcuity’s market access and reimbursement goals.

Responsibilities

• Support the Head of National Accounts & Field Reimbursement in developing and implementing strategic access initiatives with payer accounts (Commercial, Medicare, Medicaid).
• Assist with the preparation and execution of cross‑functional account plans and presentations for payer customers.
• Lead field reimbursement support for field‑based teams’ in specific sales regions post‑approval.
• Partner with Sales to equip team with clear, compliant payer and reimbursement messaging.
• Coordinate field reimbursement activities and support resources to resolve coverage, coding, and payment issues post‑approval.
• Help organize executive‑level payer meetings and follow‑up communications across internal stakeholders.
• Assist with the development and refinement of reimbursement and payer materials, including value dossiers and payer slide decks.
• Monitor account‑level activity and support execution against timeline, performance, and reporting objectives.
• Track and analyze relevant market trends and policy changes to inform payer strategy execution.
• Collaborate closely with internal partners to maintain consistent messaging and seamless customer experience.
• Act as a conduit between the field and leadership by sharing payer insights and competitive intelligence.

Qualifications

• B.S. degree with minimum 8+ years of pharmaceutical/biotech industry experience, including 5+ years in Market Access, National Accounts, or Field Reimbursement.
• Familiarity with U.S. payer systems including Commercial, Medicare, and Medicaid.
• Experience supporting oncology products (IV and/or oral).
• Proven ability to manage multiple priorities and work cross‑functionallyStrong communication, project management, and analytical skills.
• Deep understanding of UP Payer trends and established executive relationships with National/Regional and Commercial/Government plans.
• Minimum of 5 years of Oncology experience.
• Oral and IV experience.
• Demonstrated teamwork and leadership including the ability to influence without positional authority.
• Effective and agile decision making and problem‑solving skills.
• Excellent analytical skills and ability to effectively utilize available market data to understand all aspects of the market access channel landscape.
• Superior written, oral, and group communication skills.
• Must understand US pharmaceutical operations, healthcare and reimbursement landscape.
• Proven success in developing executive level approval of contract business cases including the rigorous financial analytics.

Preferred

• Experience at a small or emerging biopharmaceutical company.
• Master’s degree or advanced degree preferred.
• Previous experience launching oncology or specialty products.
• Established relationships with payer or reimbursement stakeholders is a plus.

About Us

Celcuity is a clinical‑stage, publicly traded biotechnology company seeking to extend the lives of cancer patients through the development of targeted therapies for the treatment of multiple solid tumor indications. The company was founded to develop a better way to treat the cellular drivers of tumor growth.

Our lead therapeutic candidate, gedatolisib, is an intravenously administered, potential first‑in‑class PI3K/AKT/mTOR (PAM) pathway inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. Gedatolisib phase 3 clinical development programs are focused on the treatment of patients with HR+/HER2- ABC in the 1L and 2L settings. A Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is on‑going.

Celcuity is an Equal‑Opportunity Employer

Celcuity is committed to fair and equitable compensation practices, and we strive to provide employees with total compensation packages that are competitive. For this role, the anticipated base pay range is $230,000-$250,000 DOE. The exact base pay offered for this role will depend on various factors, including but not limited to the candidate’s geography, qualifications, skills, and experience.

The successful candidate will be eligible for an annual performance incentive bonus and a new hire equity package. Celcuity also offers various benefits offerings, including, but not limited to, medical, dental, vision insurance, 401(k) match, PTO, and paid holidays.